PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

NCT03079011

Last updated date
Study Location
Institut Curie
Paris, , 75005, France
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic Breast Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Women with proven loco-regionally recurrent or metastatic adenocarcinoma of the breast not amenable to curative therapy with disease considered potentially sensitive to aromatase inhibitors Note: patients relapsing while on adjuvant tamoxifen or other non-aromatase inhibitor adjuvant endocrine therapy are eligible for the present study; patient relapsing after 6 years or more under adjuvant aromatase inhibitor are eligible.

2. Age ≥18 years;

3. Life expectancy >3 months;

4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;

5. Estrogen Receptor (ER)-positive and HER2-negative breast cancer. Where available, assessment of Estrogen Receptor status should be based on the most recent tumor sample; to be considered as ER-positive, the most recent breast cancer tissue examined must display at least 10% of cancer cells with positive ER staining;

6. Tumor block (primary tumor or metastasis) available;

7. No prior systemic anti-cancer therapy for metastatic or advanced disease (chemotherapy, targeted therapy or hormone therapy); prior initiation of LHRH agonist or bone-directed agents is however allowed);

8. Menopausal patients or patients with suppressed ovarian function Women with bilateral oophorectomy

Postmenopausal women, as defined by any of the following criteria:

Age 60 or over;

Age 50 to 59 years and meets one of the following criteria:

Amenorrhea for ≥24 months and follicle-stimulating hormone within the postmenopausal range; patients with hysterectomy or chemotherapy-induced amenorrhea must display follicle-stimulating hormone within the postmenopausal range; Other women, provided they are being treated with monthly LHRH analogues (first injection performed ≥7 days before the treatment initiation) and are willing to continue to receive LHRH agonist therapy for the duration of the trial;

9. Patients may have measurable (according to Response Evaluation Criterion in Solid Tumors (RECIST v1.1) or not measurable disease Patients with only blastic bone lesions are not eligible; Patients with only pleural, cardiac or peritoneal effusion or meningeal carcinomatosis are not eligible;

10. Adequate organ and marrow function as defined below:

Hemoglobin ≥90 g/L Absolute neutrophil count ≥1.5 G/L Platelet count ≥100 G/L Serum bilirubin ≤1.5 × upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome.

ALT and AST ≤3 × ULN; Alkaline phosphatase ≤2.5 x ULN (≤5.0 x ULN if bone or liver metastases present) Serum creatinine ≤1.5 × ULN or calculated creatinine clearance ≥ 60 mL/min as determined by Cockcroft-Gault (using actual body weight) formula for females [creatinine clearance =Weight (kg) × (140 - Age) × 0.85 (mL/min)/ (72 × serum creatinine (mg/dL))

11. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and any protocol-related procedures including screening evaluations;

12. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 4.0 Grade 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion);

13. Written informed consent obtained prior to performing any protocol-related procedures including screening evaluations;

14. Patient affiliated to a social security system.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Locally advanced breast cancer or loco-regional relapse amenable for any treatment
with curative intent;


2. Her2-positive or equivocal tumor status either on the primary or on the recurrent
tumor, defined as IHC3+, Fish/Cish amplified or Fish/Cish equivocal according to the
ASCO2015 criteria;


3. Prior endocrine therapy in the metastatic setting is not allowed;


4. Prior treatment with any CDK 4/6 inhibitor in the adjuvant or metastatic setting
(neoadjuvant/preoperative treatment is allowed); however, prior therapy with another
targeted treatment in the adjuvant setting is allowed;


5. Visceral crisis: Advanced, symptomatic, visceral spread that is at risk of
life-threatening complication in the short term and that requires chemotherapy;


6. Any major surgery (defined as requiring general anaesthesia) or significant traumatic
injury within 4 weeks of treatment initiation or patients that may require major
surgery during the course of the study; however, surgical diagnostic procedure is
allowed (even if performed under general anaesthesia);


7. Known, active bleeding diathesis;


8. Any serious known concomitant systemic disorder (e.g. known active infection including
HIV, or cardiac disease) incompatible with the study (at the discretion of
investigator), previous history of bleeding diathesis, or anti-coagulation treatment
(the use of low molecular weight heparin is allowed);


9. Patients unable to swallow tablets;


10. History of mal-absorption syndrome or other condition that would interfere with
enteral absorption;


11. Chronic daily treatment with corticosteroids with a dose of ≥ 10mg/day
methylprednisolone equivalent (excluding inhaled steroids);


12. Known active uncontrolled or symptomatic central nervous system (CNS) metastases,
carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms,
cerebral oedema, and/or progressive growth. Patients with a history of CNS metastases
or cord compression are eligible if they have been definitively treated with local
therapy (e.g., radiotherapy, stereotactic surgery) and are clinically stable and off
anticonvulsants and steroids for at least 4 weeks before treatment start;


13. Known hypersensitivity to letrozole, anastrozole, exemestane, fulvestrant, palbociclib
or any of their excipients;


14. QTcF >480 msec on basal assessment, personal history of long or short QT syndrome,
Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP);


15. Uncontrolled electrolyte disorders that can compound the effects of a QTc prolonging
drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia);


16. Patients treated within the last 7 days prior to treatment start in the trial with
drug that are known to be CYP3A4 inhibitors, drugs that are known to be CIP3A4
inducers, drugs that are known to prolong the QT interval; who underwent a grapefruit
cure;


17. Patients already included in another therapeutic trial evaluating an investigational
medicinal product or having received an investigational medicinal product within 3
months;


18. History of previous:


Any other stage II, III, IV cancer within 5 years preceding patient enrollment in the
trial - however, multiple primary breast cancers (controlateral/ipsilateral
cancers/local relapses) are allowed pending all tumor masses were ER+; Any history of
hematological malignancy;


19. Persons deprived of their freedom or under guardianship or incapable of giving
consent;


20. Pregnancy or lactation period. Women of childbearing potential must implement adequate
non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive
devices, sterilization; LHRH agonist cannot be considered as an efficient
contraceptive measure) during study treatment and for 90 days after discontinuation. A
serum pregnancy test must be negative in premenopausal women or women with amenorrhea
of less than 12 months.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Metastatic Breast CancerImproving the Approach to and Management of the Older Metastatic Breast Cancer Patient
NCT03007641
  1. Bozeman, Montana
  2. Egg Harbor Township, New Jersey
  3. Philadelphia, Pennsylvania
  4. Pottstown, Pennsylvania
  5. Wenatchee, Washington
ALL GENDERS
70 Years+
years
MULTIPLE SITES
Metastatic Breast CancerEvolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
NCT03275311
  1. Angers,
  2. Bordeaux,
  3. Caen,
  4. Clermont-ferrand,
  5. Dijon,
  6. Lille,
  7. Lyon,
  8. Marseille,
  9. Montpellier,
  10. Nantes,
  11. Nice,
  12. Paris,
  13. Reims,
  14. Rennes,
  15. Rouen,
  16. Saint-Cloud,
  17. Strasbourg,
  18. Toulouse,
  19. Villejuif,
  20. Nancy,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Metastatic Breast CancerPalbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
NCT02738866
  1. Washington, District of Columbia
  2. Annapolis, Maryland
  3. Baltimore, Maryland
  4. Pittsburgh, Pennsylvania
  5. West Reading, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Metastatic Breast CancerPhII ICb With/Without Erbitux in MBC Pts
NCT00248287
  1. Birmingham, Alabama
  2. Phoenix, Arizona
  3. Sedona, Arizona
  4. Denver, Colorado
  5. Torrington, Connecticut
  6. Melbourne, Florida
  7. New Port Richey, Florida
  8. Ocala, Florida
  9. Ocoee, Florida
  10. Chicago, Illinois
  11. Indianapolis, Indiana
  12. Overland Park, Kansas
  13. Columbia, Maryland
  14. Minneapolis, Minnesota
  15. Columbia, Missouri
  16. Saint Louis, Missouri
  17. Las Vegas, Nevada
  18. Hooksett, New Hampshire
  19. Morristown, New Jersey
  20. Summit, New Jersey
  21. Albany, New York
  22. Rexford, New York
  23. Rochester, New York
  24. Cary, North Carolina
  25. Kettering, Ohio
  26. Eugene, Oregon
  27. Seneca, South Carolina
  28. Abilene, Texas
  29. Arlington, Texas
  30. Austin, Texas
  31. Beaumont, Texas
  32. Bedford, Texas
  33. Dallas, Texas
  34. Dallas, Texas
  35. Dallas, Texas
  36. Dallas, Texas
  37. Denton, Texas
  38. El Paso, Texas
  39. Fort Worth, Texas
  40. Fredericksburg, Texas
  41. Houston, Texas
  42. Longview, Texas
  43. McAllen, Texas
  44. Mesquite, Texas
  45. Midland, Texas
  46. New Braunfels, Texas
  47. Odessa, Texas
  48. Paris, Texas
  49. Sherman, Texas
  50. Sugar Land, Texas
  51. Tyler, Texas
  52. Waco, Texas
  53. Norfolk, Virginia
  54. Salem, Virginia
  55. Edmonds, Washington
  56. Seattle, Washington
  57. Spokane, Washington
  58. Vancouver, Washington
  59. Yakima, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
Official Title  ICMJE Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients
Brief Summary This study is a randomized, open-label, multicentric, phase III trial conducted in patients receiving aromatase inhibitor and palbociclib as first line therapy for estrogen receptor (ER)-positive HER2-negative metastatic breast cancer and which aims to evaluate, at the onset of ESR1 mutations in circulating tumor DNA, the efficacy of a change of the hormone therapy (aromatase inhibitor (AI) changed to fulvestrant) combined to palbociclib, together with the safety of hormone therapy and palbociclib combination in the overall population.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Step 1: 800 patients screened for circulating blood ESR1 mutation detection at regular intervals will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off (28-day cycle) + AI (letrozole, anastrozole or exemestane) administered once daily in a continuous scheme (EoT if RECIST tumor progression or ESR1 mutation detection)

Step 2: 160 Patients with a rising circulating ESR1 mutation and without tumor progression will be randomized (1:1):

  • ARM A: no change in therapy. EoT if tumor progression or possibility of a cross-over (step 3)
  • ARM B: palbociclib 125 mg + fulvestrant 500 mg administered intramuscularly on D1,15 and 29 and once monthly thereafter. EoT if RECIST tumor progression
  • Step 3 (cross over): 80 patients who have been randomized in arm A will be offered to be treated by fulvestrant + palbociclib, after having progressed under AI + palbociclib. The EoT will occur at the tumor progression under fulvestrant + palbociclib
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Breast Cancer
Intervention  ICMJE
  • Drug: Palbociclib 125mg
    Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle
  • Drug: Aromatase Inhibitors
    Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)
    Other Name: Letrozole, Anastrozole or exemestane
  • Drug: Fulvestrant Injectable Product
    500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)
Study Arms  ICMJE
  • Experimental: A- palbociclib + AI
    After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme.
    Interventions:
    • Drug: Palbociclib 125mg
    • Drug: Aromatase Inhibitors
  • Experimental: B- Palbociclib + fulvestrant
    After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with fulvestrant, a selective estrogen receptor down-regulator, 500 mg administered intramuscularly on Days 1, 15, and 29 and once monthly thereafter.
    Interventions:
    • Drug: Palbociclib 125mg
    • Drug: Fulvestrant Injectable Product
  • Experimental: Selection - Palbociclib + AI
    All patients included into the study will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme
    Interventions:
    • Drug: Palbociclib 125mg
    • Drug: Aromatase Inhibitors
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: March 7, 2017)
800
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 15, 2024
Estimated Primary Completion Date April 15, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Women with proven loco-regionally recurrent or metastatic adenocarcinoma of the breast not amenable to curative therapy with disease considered potentially sensitive to aromatase inhibitors Note: patients relapsing while on adjuvant tamoxifen or other non-aromatase inhibitor adjuvant endocrine therapy are eligible for the present study; patient relapsing after 6 years or more under adjuvant aromatase inhibitor are eligible.
  2. Age ?18 years;
  3. Life expectancy >3 months;
  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;
  5. Estrogen Receptor (ER)-positive and HER2-negative breast cancer. Where available, assessment of Estrogen Receptor status should be based on the most recent tumor sample; to be considered as ER-positive, the most recent breast cancer tissue examined must display at least 10% of cancer cells with positive ER staining;
  6. Tumor block (primary tumor or metastasis) available;
  7. No prior systemic anti-cancer therapy for metastatic or advanced disease (chemotherapy, targeted therapy or hormone therapy); prior initiation of LHRH agonist or bone-directed agents is however allowed);
  8. Menopausal patients or patients with suppressed ovarian function Women with bilateral oophorectomy

    Postmenopausal women, as defined by any of the following criteria:

    Age 60 or over;

    Age 50 to 59 years and meets one of the following criteria:

    Amenorrhea for ?24 months and follicle-stimulating hormone within the postmenopausal range; patients with hysterectomy or chemotherapy-induced amenorrhea must display follicle-stimulating hormone within the postmenopausal range; Other women, provided they are being treated with monthly LHRH analogues (first injection performed ?7 days before the treatment initiation) and are willing to continue to receive LHRH agonist therapy for the duration of the trial;

  9. Patients may have measurable (according to Response Evaluation Criterion in Solid Tumors (RECIST v1.1) or not measurable disease Patients with only blastic bone lesions are not eligible; Patients with only pleural, cardiac or peritoneal effusion or meningeal carcinomatosis are not eligible;
  10. Adequate organ and marrow function as defined below:

    Hemoglobin ?90 g/L Absolute neutrophil count ?1.5 G/L Platelet count ?100 G/L Serum bilirubin ?1.5 × upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome.

    ALT and AST ?3 × ULN; Alkaline phosphatase ?2.5 x ULN (?5.0 x ULN if bone or liver metastases present) Serum creatinine ?1.5 × ULN or calculated creatinine clearance ? 60 mL/min as determined by Cockcroft-Gault (using actual body weight) formula for females [creatinine clearance =Weight (kg) × (140 - Age) × 0.85 (mL/min)/ (72 × serum creatinine (mg/dL))

  11. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and any protocol-related procedures including screening evaluations;
  12. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 4.0 Grade 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion);
  13. Written informed consent obtained prior to performing any protocol-related procedures including screening evaluations;
  14. Patient affiliated to a social security system.

Exclusion Criteria:

  1. Locally advanced breast cancer or loco-regional relapse amenable for any treatment with curative intent;
  2. Her2-positive or equivocal tumor status either on the primary or on the recurrent tumor, defined as IHC3+, Fish/Cish amplified or Fish/Cish equivocal according to the ASCO2015 criteria;
  3. Prior endocrine therapy in the metastatic setting is not allowed;
  4. Prior treatment with any CDK 4/6 inhibitor in the adjuvant or metastatic setting (neoadjuvant/preoperative treatment is allowed); however, prior therapy with another targeted treatment in the adjuvant setting is allowed;
  5. Visceral crisis: Advanced, symptomatic, visceral spread that is at risk of life-threatening complication in the short term and that requires chemotherapy;
  6. Any major surgery (defined as requiring general anaesthesia) or significant traumatic injury within 4 weeks of treatment initiation or patients that may require major surgery during the course of the study; however, surgical diagnostic procedure is allowed (even if performed under general anaesthesia);
  7. Known, active bleeding diathesis;
  8. Any serious known concomitant systemic disorder (e.g. known active infection including HIV, or cardiac disease) incompatible with the study (at the discretion of investigator), previous history of bleeding diathesis, or anti-coagulation treatment (the use of low molecular weight heparin is allowed);
  9. Patients unable to swallow tablets;
  10. History of mal-absorption syndrome or other condition that would interfere with enteral absorption;
  11. Chronic daily treatment with corticosteroids with a dose of ? 10mg/day methylprednisolone equivalent (excluding inhaled steroids);
  12. Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral oedema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated with local therapy (e.g., radiotherapy, stereotactic surgery) and are clinically stable and off anticonvulsants and steroids for at least 4 weeks before treatment start;
  13. Known hypersensitivity to letrozole, anastrozole, exemestane, fulvestrant, palbociclib or any of their excipients;
  14. QTcF >480 msec on basal assessment, personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP);
  15. Uncontrolled electrolyte disorders that can compound the effects of a QTc prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia);
  16. Patients treated within the last 7 days prior to treatment start in the trial with drug that are known to be CYP3A4 inhibitors, drugs that are known to be CIP3A4 inducers, drugs that are known to prolong the QT interval; who underwent a grapefruit cure;
  17. Patients already included in another therapeutic trial evaluating an investigational medicinal product or having received an investigational medicinal product within 3 months;
  18. History of previous:

    Any other stage II, III, IV cancer within 5 years preceding patient enrollment in the trial - however, multiple primary breast cancers (controlateral/ipsilateral cancers/local relapses) are allowed pending all tumor masses were ER+; Any history of hematological malignancy;

  19. Persons deprived of their freedom or under guardianship or incapable of giving consent;
  20. Pregnancy or lactation period. Women of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization; LHRH agonist cannot be considered as an efficient contraceptive measure) during study treatment and for 90 days after discontinuation. A serum pregnancy test must be negative in premenopausal women or women with amenorrhea of less than 12 months.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03079011
Other Study ID Numbers  ICMJE UC-0140/1615 - UCBG3-05
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party UNICANCER
Study Sponsor  ICMJE UNICANCER
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:François-Clément BIDARD, MD PhDInstitut Curie
PRS Account UNICANCER
Verification Date March 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP